rFIXFc

BIOLOGICAL5 trials

Conditions

Hemophilia AHemophilia BSevere Hemophilia B

Phase 1

Phase I/IIa Study of FIXFc in Hemophilia B Patients

CompletedNCT00716716

Bioverativ Therapeutics Inc.Hemophilia B

Start: 2008-04-30End: 2009-10-31Updated: 2020-12-19

Phase 3

Long-Term Safety and Efficacy of rFIXFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia B

CompletedNCT01425723

Bioverativ Therapeutics Inc.Severe Hemophilia B

Start: 2011-12-08End: 2017-10-31Updated: 2020-12-19

Study of Recombinant Coagulation Factor IX Fc Fusion Protein, BIIB029, in Previously Treated Pediatric Participants With Hemophilia B

CompletedNCT01440946

Bioverativ Therapeutics Inc.Hemophilia B

Start: 2012-06-30End: 2014-11-30Updated: 2020-12-19

Study to Determine the Safety and Efficacy of rFIXFc in Previously Untreated Males With Severe Hemophilia B

CompletedNCT02234310

Bioverativ, a Sanofi companyHemophilia B

Start: 2014-11-13End: 2019-08-20Updated: 2022-03-25

Unknown Phase

Fc factOrs and Real-World hemophiliA Patient-ReporteD Outcomes

TerminatedNCT02392156

Bioverativ Therapeutics Inc.Hemophilia A, Hemophilia B

Start: 2015-07-31End: 2015-12-31Updated: 2020-12-19

European Journal Of Haematology2024-06-25

Post hoc longitudinal assessment of the efficacy and safety of recombinant factor IX Fc fusion protein in hemophilia B

Blood Advances2023-02-275 citations

Recombinant factor IX Fc prophylaxis reduces pain and increases levels of physical activity, with sustained, long-term improvements in patients with hemophilia B: <i>post hoc</i> analysis of phase III trials using patient-reported outcomes

Therapeutic Advances in Hematology2023-01-013 citations

Prophylaxis with rFIXFc Reduces the Frequency and Delays Time to First Spontaneous Bleed Event in Previously Untreated Patients with Hemophilia B: A Post Hoc Analysis of the PUPs B-LONG Trial

Blood2021-11-05

Final results of the PUPs B-LONG study: evaluating safety and efficacy of rFIXFc in previously untreated patients with hemophilia B

Blood Advances2021-07-0925 citations

Long‐term safety and sustained efficacy for up to 5 years of treatment with recombinant factor IX Fc fusion protein in subjects with haemophilia B: Results from the B‐YOND extension study

Haemophilia2020-06-0444 citations

Extending recombinant factor IX Fc fusion protein dosing interval to 14 or more days in patients with hemophilia B.

2018-11-299 citations

B-YOND Final Results Confirm Established Safety, Sustained Efficacy, and Extended Dosing Interval for Up to 4 Years of Treatment With rFIXFc in Previously Treated Subjects With Severe Hemophilia B

Blood2018-11-295 citations

Recombinant factor IX Fc fusion protein in children with haemophilia B (Kids B-LONG): results from a multicentre, non-randomised phase 3 study.

2017-02-0159 citations

Clinical Outcomes in Adults/Adolescents with Hemophilia B Treated Long Term with Recombinant Factor IX Fc Fusion Protein (rFIXFc) Prophylaxis: Interim Results of the B-Yond Extension Study

Blood2016-12-021 citations

Long Term Safety and Efficacy of Recombinant Factor IX Fc Fusion Protein (rFIXFc) Prophylaxis in Children with Hemophilia B: Interim Results of the B-Yond Extension Study

Blood2016-12-021 citations

Extended-Interval Prophylaxis with rFIXFc in Adults and Adolescents with Hemophilia B: Interim Results of the B-YOND Extension Study

Blood2015-12-031 citations

Clinical Outcomes in Children with Hemophilia B Treated Long Term with rFIXFc: Interim Results of the B-YOND Extension Study

Blood2015-12-03

Pharmacokinetics Of Recombinant Factor IX Fc Fusion Protein (rFIXFc) In Pediatric Subjects With Hemophilia B: An Interim Analysis Of The Kids B-LONG Study

Blood2013-11-153 citations

Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients.

2011-11-22123 citations

rFIXFc

Sponsors

Conditions

Phase 1

Phase 3

Unknown Phase

Related Papers